Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 15Squamous Cell Carcinoma of Head and Neck 11Small Cell Lung Carcinoma 9Lung Neoplasms 9Oropharyngeal Neoplasms 7Mouth Neoplasms 6Laryngeal Neoplasms 6Carcinoma 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Stomach Neoplasms 4Hypopharyngeal Neoplasms 4Breast Neoplasms 4Adenocarcinoma of Lung 4Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2Salivary Gland Neoplasms 2Recurrence 2Paranasal Sinus Neoplasms 2Ovarian Neoplasms 2Medulloblastoma 2Lymphoid Interstitial Pneumonia 2Liver Neoplasms 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Anus Neoplasms 2Urethral Neoplasms 1

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sinonasal Squamous Cell Carcinoma × Platinum × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡